Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients

Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients

Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 specific monoclonal antibodies (mAb) or convalescent plasma represents a considerable treatment option to protect these patients...

Full description

Bibliographic Details
Main Authors: Laura Thümmler, Monika Lindemann, Peter A. Horn, Veronika Lenz, Margarethe Konik, Anja Gäckler, Kristina Boss, Fotis Theodoropoulos, Vasiliki Besa, Christian Taube, Thorsten Brenner, Oliver Witzke, Adalbert Krawczyk, Hana Rohn
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Viruses
Subjects:
SARS-CoV-2
convalescent plasma
monoclonal antibody treatment
Coronavirus Disease 19
Online Access:https://www.mdpi.com/1999-4915/15/1/119

Similar Items

Similar Items